Amy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses the trials for deuruxolitinib, an FDA-approved treatment for alopecia areata. Deuruxolitinib has shown significant improvement in clinical trials compared to placebo, with a twice-daily dose of 8 mg. The trials, which included adults of various ethnicities, showed no serious adverse events, though herpes zoster and upper respiratory infections were noted. Deuruxolitinib is 1 of 3 other Janus kinase inhibitors for severe alopecia areata, offering a safer alternative to long-term corticosteroids and improving patients’ quality of life by regrowing hair and enhancing overall well-being.
